Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study Clearside Biomedical's CLS-AX Phase 2b trial for wet AMD met primary and secondary endpoints ...
The S&P 500 also rose, gaining, 0.78% to 5,218.70. Avi Kapoor Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Shares of ...
Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback